Information on

COVID-19

The Sickle Cell Disease Association of America’s (SCDAA’s) Medical Research and Advisory Committee (MARAC) and others have published important information on how COVID-19 impacts SCD patients. In addition to following the directions of federal, state and local health officials, this information may be helpful.

COVID-19 information can change. Please visit www.sicklecelldisease.org for possible updates.

GET IN TOUCH

We'd Love to Hear from You

Whether you are looking to learn more about our services, and how we can help, or you’re looking for volunteer opportunities, to make a donation, or have any questions about the Maryland Sickle Cell Disease Association, please reach out!
CONTACT US
KEEP IN TOUCH
Sign up for our email list, or follow us on social media, to stay in-the-know about the Maryland Sickle Cell Disease Association
Scroll to Top

Breaking News

FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

On December 8, 2023, “The U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signaling an innovative advancement in the field of gene therapy."